Cookies on this website
We use cookies to ensure that we give you the best experience on our website. If you click 'Continue' we'll assume that you are happy to receive all cookies and you won't see this message again. Click 'Find out more' for information on how to change your cookie settings.

We evaluated the humoral and cellular immunogenicity of adjuvanted and non-adjuvanted H5N1 influenza vaccine in two groups of 300 adults: aged 18-60 and >60 years in a randomized, open-label, uncontrolled phase 2 trial. Participants received two injections (D0, D21) of 7.5 microg hemagglutinin without adjuvant or 30 microg with aluminum hydroxide adjuvant. Antibody responses and cytokine secretion were assessed before and after vaccination. Excluding the 6/300 non-elderly and 47/300 elderly participants with pre-existing antibodies, geometric mean titers (dil(-1)) on D42 were higher with 30 microg+Ad and were comparable between age groups. Participants with pre-existing antibodies responded strongly to the first vaccination (GMTs in the range 147-228 on D21). Vaccination increased both Th1 and Th2 T-cell responses. The predominantly Th1 profile observed before vaccination was unaffected by vaccination. H5N1 influenza vaccine is no less immunogenic in elderly adults than in younger adults and, due to a higher proportion non-naïve elderly, immunogenicity was higher in this latter group.

Original publication

DOI

10.1016/j.vaccine.2009.08.110

Type

Journal article

Journal

Vaccine

Publication Date

16/11/2009

Volume

27

Pages

6918 - 6925

Keywords

Adjuvants, Immunologic, Adult, Aged, Aluminum Hydroxide, Antibodies, Viral, Cytokines, Female, Hemagglutinin Glycoproteins, Influenza Virus, Humans, Immunity, Cellular, Immunity, Humoral, Immunization, Secondary, Influenza A Virus, H5N1 Subtype, Influenza Vaccines, Influenza, Human, Male, Middle Aged, Th1 Cells, Th2 Cells, Young Adult